Drug Approval | March 21, 2023
Caplin receives USFDA approval for Rocuronium Bromide Injection
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Thiamine Hydrochloride Injection is effective in the treatment of vitamin B1 deficiency (beriberi)
Fluorouracil Injection is indicated for the treatment of patients with adenocarcinoma of colon and rectum and breast
Rocuronium Bromide Injection is a neuromuscular blocking agent
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
The new sterile filling line meets cGMP aseptic filling regulatory requirements
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
Subscribe To Our Newsletter & Stay Updated
